Kura Oncology, Inc.

This #BloodCancerAwarenessMonth, join us in recognizing, supporting, and uplifting patients living with blood cancer – we see you, and you are not alone.     Kura is deeply committed to advancing therapies to address the unmet need in #bloodcancer treatments, including NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (#AML). See our CMO Stephen Dale, M.D.’s thoughts on the progress and future of targeted therapies for blood cancers.    Learn more about our investigational menin inhibitor for AML: https://lnkd.in/gsQRH6z3     #CancelBloodCancer #BCAM24 

More than 1000 people are diagnosed with #leukemia every day; however, the nonspecific signs and symptoms make it difficult to recognize. On #WorldLeukemiaDay, join Kura Oncology and Acute Leukemia Advocates Network in raising awareness of the signs and symptoms of this condition. By helping more people get diagnosed earlier, we can help reduce the number of preventable deaths and improve outcomes. See the most common symptoms and #BeLeukemiaAware: https://bit.ly/3MuHAFi #WLD24 Learn more about Kura’s commitment to helping patients with acute leukemia lead better, longer lives: https://bit.ly/4dPuwGs

Visit us at SOHO 2024, Booth #154, and learn the latest on the KOMET clinical trial program and ziftomenib, an investigational menin inhibitor, in acute leukemias. KOMET-001 phase 2 registration-enabling study in R/R NPM1-m AML: Enrollment complete KOMET-007 and KOMET-008 phase 1 ziftomenib combination studies in newly diagnosed or R/R NPM1-m or KMT2A-r AML: Actively recruiting Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation by the FDA for R/R NPM1-m AML. Find out more about ziftomenib at #SOHO2024. More on the KOMET clinical trials is available here: https://bit.ly/3RUb9mS

With advancements in technology and an enhanced understanding of cancer biology, we can now both treat cancer once it’s developed, and identify ways to prevent new cancerous cells from forming. In a recent Empowered Patient Podcast episode with host Karen Jagoda, our Executive Vice President of Clinical Development, Mollie Leoni, MD explains how our menin inhibitor #ziftomenib targets key mutations that trigger the onset of #AML, promoting differentiation of cancerous cells into normal cells, and potentially halting the disease. Listen to the full podcast episode here: https://lnkd.in/gSNPnx8E

Menin inhibitors, including #ziftomenib, show potential to treat acute leukemias including NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (#AML). In a recent Nature article, Ken Garber breaks down the menin inhibitor space, including targets, data to date, and the potential menin inhibitors have to provide a new hope to patients.   Read the full article here: https://bit.ly/3X8GfKE 

The recent completion of the KOMET-001 trial enrollment is not only a major milestone for the many clinical investigators who work tirelessly for their patients, but is also an important step in advancing AML treatment. Early data indicate that this milestone brings us closer to realizing the potential of ziftomenib and better understanding NPM1-m AML. Discover the latest on KOMET-001 and actively recruiting KOMET trials in AML: https://bit.ly/3xL3bWd

Kura CEO Troy Wilson, Ph.D., J.D. joined fellow panelists at #FierceJPM Week to discuss the balancing of multiple factors— including market demand, legislation, patient interest and company resources— in efficiently advancing #drugdevelopment.    Hear more in the clip below and view more highlights from the panel here: https://bit.ly/46HsLIK 

Today we announced our Q2 2024 #earnings and shared updates on business and pipeline milestones as we look toward the rest of the year.     View the full release: https://bit.ly/4fyKPZz   Tune in to our investor webcast call today at 4:30 p.m. ET.  

Our IND application for ziftomenib in advanced gastrointestinal stromal tumors (GIST) has been cleared by the FDA.     This milestone represents the first IND clearance of a menin inhibitor to treat #GIST, a solid tumor indication with limited available treatment options for patients. Stay tuned as we present preclinical data supporting #ziftomenib’s potential to treat GIST in combination with imatinib at an upcoming scientific meeting and initiate a proof-of-concept clinical study early next year.    Read the full announcement: https://lnkd.in/e8HapyA5

We’re grateful to our partners and friends at Life Science Cares San Diego and Mama's Kitchen for providing us an avenue to give back to our community. #ICYMI - in June, our partnership allowed us to provide support to critically ill patients struggling with food insecurity in San Diego.     Hear more about our partnership efforts from our President and CEO Troy Wilson, Ph.D., J.D. as he recaps the event: https://bit.ly/3Szu46P